MedTrace Logo

Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE)

NCT01101802 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2011-09-28

No results posted yet for this study

Summary

Systemic lupus erythematosus (SLE) is an independent risk factor for atherosclerosis. Endothelial dysfunction is the earliest marker of atherosclerosis and is measured by flow mediated dilation (FMD) of the brachial artery. The purpose of the study was to measure FMD in mild, stable SLE patients and look for change in FMD with the immunosuppressant drug mycophenolate mofetil (MMF).

Conditions

Interventions

DRUG

Mycophenolate mofetil

Arm 1 patients were given 1 gm bd mycophenolate mofetil for 8 weeks, The mycophenolate was dispensed as 500mg tablets.

DRUG

sugar pill

Arm 2 patients were given 2 sugar pills bd for 8 weeks

Sponsors & Collaborators

  • Institute of Child Health, University College London, London, UK.

    collaborator UNKNOWN

  • Guy's and St Thomas' NHS Foundation Trust

    lead OTHER

Principal Investigators

  • David P D'Cruz, MD, FRCP · Guy's and St Thomas' NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-03-31
Completion
2008-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01101802 on ClinicalTrials.gov